Lebwohl M, Strober B, Linaberry M, Hoyt K, Banerjee S, Kisa RM, Mehta NN. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2023 Mar. 13 [cited 2024 Jul. 4];7(2):s115. Available from: https://jofskin.org/33014/index.php/skin/article/view/1966